Insmed, Inc. (NASDAQ:INSM) Insider Sells $72,114.68 in Stock

Insmed, Inc. (NASDAQ:INSM - Get Free Report) insider Michael Alexander Smith sold 748 shares of the business's stock in a transaction dated Friday, July 11th. The shares were sold at an average price of $96.41, for a total transaction of $72,114.68. Following the completion of the transaction, the insider owned 67,327 shares in the company, valued at approximately $6,490,996.07. This trade represents a 1.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Michael Alexander Smith also recently made the following trade(s):

• On Tuesday, July 15th, Michael Alexander Smith sold 933 shares of Insmed stock. The shares were sold at an average price of $102.51, for a total transaction of $95,641.83.
• On Thursday, June 5th, Michael Alexander Smith sold 1,879 shares of Insmed stock. The shares were sold at an average price of $73.50, for a total transaction of $138,106.50.
• On Tuesday, June 3rd, Michael Alexander Smith sold 1,448 shares of Insmed stock. The shares were sold at an average price of $71.50, for a total transaction of $103,532.00.
• On Wednesday, May 14th, Michael Alexander Smith sold 409 shares of Insmed stock. The stock was sold at an average price of $65.61, for a total transaction of $26,834.49.
• On Tuesday, May 13th, Michael Alexander Smith sold 4,407 shares of Insmed stock. The stock was sold at an average price of $67.81, for a total transaction of $298,838.67.

Insmed Stock Down 0.4%

Shares of Insmed stock traded down $0.42 on Thursday, hitting $104.17. The company had a trading volume of 1,998,170 shares, compared to its average volume of 2,300,433. The firm has a market capitalization of $19.76 billion, a P/E ratio of -17.51 and a beta of 0.90. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $106.83. The company has a debt-to-equity ratio of 11.38, a current ratio of 5.86 and a quick ratio of 5.44. The stock has a 50-day moving average of $85.41 and a 200-day moving average of $78.02.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative return on equity of 446.98% and a negative net margin of 265.93%. The business had revenue of $92.82 million for the quarter, compared to analyst estimates of $91.63 million. During the same quarter in the previous year, the company posted ($1.06) EPS. The business's revenue for the quarter was up 22.9% compared to the same quarter last year. Research analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Cullen Frost Bankers Inc. boosted its holdings in Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 221 shares during the last quarter. Elequin Capital LP bought a new stake in Insmed during the fourth quarter worth $28,000. ORG Partners LLC raised its position in Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 196 shares in the last quarter. Steward Partners Investment Advisory LLC raised its position in Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 163 shares in the last quarter. Finally, NBC Securities Inc. bought a new stake in Insmed during the first quarter worth $49,000.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on INSM. JPMorgan Chase & Co. boosted their target price on shares of Insmed from $90.00 to $111.00 and gave the stock an "overweight" rating in a research note on Tuesday, July 8th. Citigroup raised shares of Insmed to a "buy" rating in a research note on Tuesday, June 10th. Morgan Stanley boosted their price target on shares of Insmed from $102.00 to $108.00 and gave the stock an "overweight" rating in a research note on Thursday. Wells Fargo & Company boosted their price target on shares of Insmed from $107.00 to $119.00 and gave the stock an "overweight" rating in a research note on Wednesday, June 11th. Finally, The Goldman Sachs Group boosted their price target on shares of Insmed from $100.00 to $112.00 and gave the stock a "buy" rating in a research note on Wednesday, June 11th. One research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, Insmed has an average rating of "Moderate Buy" and an average price target of $108.47.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.